Highlights Evaxion A/S

Equities

EVAX

US29970R3030

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 00:00:00 14/03/2026 +04			5-day change	1st Jan Change
4.260 ^USD	+1.91%		+32.30%	-10.69%

03-13	European Equities Traded in the US as American Depositary Receipts Decline in Friday Trading	MT
03-12	European Equities Traded in US as ADRs Slump in Thursday Trading	MT

Highlights

03-05	Evaxion A/S Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
01-13	Evaxion A/S Expands AI-Immunology Platform Into Autoimmune Diseases	CI
12-19	Evaxion A/S Provides Update on MSD Collaboration - Retains Global Rights to Gonorrhea Vaccine Candidate EVX-B2	CI
12-08	Evaxion A/S Presents New Data for EVX-04, a Cancer Vaccine Candidate for Acute Myeloid Leukemia at ASH Annual Meeting	CI
11-21	Evaxion A/S prospectus relates to offer and sale by selling shareholder of up to 38,450,000 ordinary shares	RE
11-20	Evaxion A/S Announces Positive Data for Lead Antigens in Cytomegalovirus Vaccine Program Evx-V1	CI
11-07	Evaxion A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
11-06	Techbio firm Evaxion posts Q3 net income of $4.6 mln	RE
11-03	Evaxion A/S Expands R&D Pipeline with New AI- Designed Precision Cancer Vaccine Candidate	CI
27/10/25	Evaxion A/S Announces Chief Executive Office Changes	CI
17/10/25	Evaxion A/S Announces New Two-Year Unprecedented Clinical Efficacy Data of Its Personalized Cancer Vaccine EVX-01 in Patients with Advanced Melanoma	CI
03/10/25	Evaxion A/S to Present New Biomarker Data for AI- Designed Personalized Cancer Vaccine EVX-01 At the SITC 2025 Annual Meeting	CI
25/09/25	The Waiting Game
25/09/25	Evaxion A/S Announces Out-Licensing of Vaccine Candidate EVX-B3 to MSD with Cash Payment	CI
14/08/25	Evaxion A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
25/07/25	Evaxion A/S to Present Two-Year Clinical Efficacy Data from Phase 2 Trial with AI- Designed Personalized Cancer Vaccine EVX-01 at the ESMO Congress 2025	CI
25/06/25	Evaxion Expands R&D Pipeline with New Vaccine Program Targeting Group A Streptococcus	CI
27/05/25	Evaxion A/S Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
22/05/25	Evaxion Doses First Patient in Extension of Phase 2 Trial Exploring the Full Potential of Ai- Designed Personalized Cancer Vaccine Evx-01	CI
28/04/25	Evaxion Biotech A/S Announces New Data Underscoring the Ability of Cancer Vaccine EVX-01	CI
28/04/25	Evaxion Biotech A/S Presents striking EVX-01 Data at the AACR Annual Meeting	CI
01/04/25	Evaxion A/S Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024	CI
26/03/25	Evaxion Biotech A/S to Present New Phase 2 Data for AI- Designed Cancer Vaccine EVX-01 at AACR Annual Meeting	CI
25/02/25	Evaxion Biotech A/S Extends Phase 2 Trial with AI-Immunology??	CI
04/02/25	Top Premarket Gainers	MT